Patients scheduled administration of glucocorticoid
Conditions
Interventions
Concomitant administration of linagliptin at start of GC administration
Sponsors
Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Administration of 20mg/day or more of prednisone is scheduled 2) Not fulfilled below criteria for diabetes mellitus a) HbA1c >= 6.5 % b) fasting blood glucose level >= 126 mg/dL c) blood glucose level at 2hr on OGTT >= 200mg/dL or casual blood glucose level >= 200mg/dL 3) At least either one of following risk factor for glucocorticoid induced diabetes mellitus a) eGFR =< 60ml/min/1.73m2 b) 65 year or older c) HbA1c > 6.0 % 4) Informed consent is obtained
Exclusion criteria
Exclusion criteria: 1) < 20 years old 2) Inability of internal use 3) Pregnancy 4) Glucocorticoid pulse therapy is scheduled 5) Malignancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Proportion of development of glucocorticoid induced diabetes mellitus within 1 month | — |
Secondary
| Measure | Time frame |
|---|---|
| Concomitant insulin use Concomitant anti-diabetic drug Adverse effect Change in HbAic Change in HOMA-IR Change in glycoalbumin Change in 1.5-AG Change in adiponectin Change in glucagon Change in cortisol Change in leptin Change in serum and urine CPR | — |
Countries
Japan
Contacts
Public ContactYoshia Miyawaki
Okayama University Graduate Schoolof of Medicine, Dentistry and Pharmaceutical Sciences Department of Nephrology, Rheumatology, Endocrinology and Metabolism
Outcome results
None listed